Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
World J Gastroenterol ; 14(37): 5641-9, 2008 Oct 07.
Article in English | MEDLINE | ID: mdl-18837079

ABSTRACT

The formation of bile depends on the structural and functional integrity of the bile-secretory apparatus and its impairment, in different situations, results in the syndrome of cholestasis. The structural bases that permit bile secretion as well as various aspects related with its composition and flow rate in physiological conditions will first be reviewed. Canalicular bile is produced by polarized hepatocytes that hold transporters in their basolateral (sinusoidal) and apical (canalicular) plasma membrane. This review summarizes recent data on the molecular determinants of this primary bile formation. The major function of the biliary tree is modification of canalicular bile by secretory and reabsorptive processes in bile-duct epithelial cells (cholangiocytes) as bile passes through bile ducts. The mechanisms of fluid and solute transport in cholangiocytes will also be discussed. In contrast to hepatocytes where secretion is constant and poorly controlled, cholangiocyte secretion is regulated by hormones and nerves. A short section dedicated to these regulatory mechanisms of bile secretion has been included. The aim of this revision was to set the bases for other reviews in this series that will be devoted to specific issues related with biliary physiology and pathology.


Subject(s)
Bile Canaliculi/metabolism , Bile Ducts/metabolism , Bile/metabolism , Animals , Bile Acids and Salts/metabolism , Hepatocytes/metabolism , Humans , Membrane Transport Proteins/metabolism
2.
J Hypertens ; 25(12): 2486-96, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17984671

ABSTRACT

OBJECTIVES: D/L-Nebivolol is a lypophilic beta1-adrenergic antagonist which is devoid of intrinsic sympathomimetic activity and can increase nitric oxide (NO) bioavailability with its subsequent vasodilating properties. The purpose of the present work was to assess the effect of long-term nebivolol administration on both renal damage and endothelial dysfunction induced by renal mass reduction (RMR) in rats. Atenolol, which does not increase NO bioavailability, was included in the study as a comparative beta-adrenoceptor antagonist. METHODS: Rats were subjected to both right nephrectomy and surgical removal of two-thirds of the left kidney in order to retain approximately one-sixth of the total renal mass. One week after ablation, rats were distributed randomly according to the following experimental groups: control group containing RMR rats without treatment; RMR rats treated daily with nebivolol for 6 months (drinking water, 8 mg/kg per day); and RMR rats treated daily with atenolol for 6 months (drinking water, 80 mg/kg per day). A group of sham-operated animals was also included. RESULTS: Administration of either nebivolol or atenolol similarly reduced arterial pressure in comparison with RMR untreated animals; however, animals receiving nebivolol presented lower levels of collagen type I expression as well as lower glomerular and interstitial fibrosis than those receiving atenolol. Urinary excretion of oxidative stress markers were also lower in animals receiving nebivolol than in rats treated with atenolol. Furthermore, nebivolol prevented RMR-induced endothelial dysfunction more efficiently than atenolol. CONCLUSIONS: Nebivolol protects against renal fibrosis, oxidative stress and endothelial dysfunction better than equivalent doses, in terms of arterial pressure reduction, of atenolol in a hypertensive model of renal damage induced by RMR.


Subject(s)
Adrenergic beta-Antagonists/administration & dosage , Benzopyrans/administration & dosage , Ethanolamines/administration & dosage , Hypertension, Renal/drug therapy , Animals , Dinoprost/analogs & derivatives , Dinoprost/metabolism , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiopathology , Fibrosis , Hypertension, Renal/pathology , Hypertension, Renal/physiopathology , Kidney/drug effects , Kidney/pathology , Kidney/physiopathology , Male , Nebivolol , Oxidative Stress/drug effects , Rats , Rats, Wistar , Thiobarbituric Acid Reactive Substances/metabolism
3.
Eur J Pharmacol ; 557(2-3): 221-9, 2007 Feb 28.
Article in English | MEDLINE | ID: mdl-17184768

ABSTRACT

We examined the ability of the flavonoids quercetin and kaempferol to modulate inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) and reactive C-protein (CRP) expression, and to induce changes in the nuclear factor kappa B (NF-kappaB) pathway in the human hepatocyte-derived cell line Chang Liver. Cells were incubated with a cytokine mixture supplemented with quercetin or kaempferol (5 to 200 micromol/l). Kaempferol produced a significant concentration-dependent decrease of iNOS, COX-2 and CRP protein level at all concentrations, but the percentage of inhibition induced by quercetin was reduced at high concentrations. Both flavonoids significantly inhibited mRNA level of iNOS, COX-2, and CRP. Inhibitory effects by quercetin and kaempferol were also observed on NF-kappaB activation and on protein concentration of the phosphorylated form of the inhibitor IkappaB alpha and of IKK (IkappaB kinase)alpha. The present study suggests that the modulation of iNOS, COX-2 and CRP by quercetin or kaempferol may contribute to the anti-inflammatory effects of these two structurally similar flavonoids in Chang Liver cells, via mechanisms likely to involve blockade of NF-kappaB activation and the resultant up-regulation of the pro-inflammatory genes. Our data also indicate that the minor structural differences between both compounds determine differences in their inhibitory capacity.


Subject(s)
C-Reactive Protein/antagonists & inhibitors , Cyclooxygenase 2/metabolism , Hepatocytes/drug effects , Kaempferols/pharmacology , NF-kappa B/metabolism , Nitric Oxide Synthase Type II/antagonists & inhibitors , Quercetin/pharmacology , C-Reactive Protein/analysis , Cell Line , Cyclooxygenase 2/analysis , Dose-Response Relationship, Drug , Down-Regulation , Flavonols/chemistry , Flavonols/pharmacology , Hepatocytes/enzymology , Humans , Kaempferols/chemistry , Molecular Structure , Nitric Oxide Synthase Type II/analysis , Quercetin/chemistry
4.
Hepatol Res ; 32(1): 58-65, 2005 May.
Article in English | MEDLINE | ID: mdl-15905118

ABSTRACT

An increased expression and activity of the heme oxygenase-1 (HO-1) in the liver has been observed in models of hepatic damage. Nitric oxide (NO) seems to be involved in HO-1 regulation. The aim of this work is to assess HO-1 induction and heme oxygenase (HO) activity in rats with bile duct ligation (BDL). We have assessed the effect of chronic inhibition of the NO synthesis by N(G)-nitro-l-arginine methyl ester (l-NAME) on HO-1 induction and HO activity. In the BDL animals, compared with sham-operated ones, we found an increased plasma nitrite and bilirubin concentration, and a marked liver expression of inducible nitric oxide synthase and HO-1, assessed by both Western blot and immunohistochemistry. Chronic l-NAME treatment prevented plasma nitrite increase in animals subjected to BDL. BDL animals treated with l-NAME, compared with untreated BDL rats, showed an important decrease in HO-1 expression and in HO activity (assessed as a decreased plasma bilirubin and bilirubin excretion). In conclusion, our experiments show parallel changes in expression and activity of HO-1 and NOS2 activity in the BDL model of liver damage and suggest that increased NO production is involved in HO-1 overexpression.

SELECTION OF CITATIONS
SEARCH DETAIL
...